PBYI

Puma Biotechnology, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:48 UTC

Last close

10.69USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-26

13.3xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
25.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
The filing itself
13.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
18.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
0.22Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.32 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.05x

-0.41x

-2.00x

0.29x

0.55x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales1.05x
Its own average over 9 years, 216.9M.
Profit-0.41x
Its own average over 10 years, -76.3M.
Free cash flow-2.00x
Its own average over 10 years, -20.8M.
Debt0.29x
Its own average over 9 years, 98.5M.
Price0.55x
Its own average over 11 years, 19. Market data, 2026-11-04

Free cash flow is furthest from its own average, at -2.00 times.

Sales is 1.05 times its own 9-year average; Profit is -0.41 times its own 10-year average; Free cash flow is -2.00 times its own 10-year average; Debt is 0.29 times its own 9-year average; Price is 0.55 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales against its own 9-year average1.05
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
Profit against its own 10-year average-0.41
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
Free cash flow against its own 10-year average-2.00
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
Debt against its own 9-year average0.29
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
Price against its own 11-year average0.55Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD